Obg plays a significant role in temperature sensitivity of Mycoplasma synoviae live attenuated vaccine strain MS-H.
Mycoplasma
Temperature sensitivity
Thermoadaptive evolution
Journal
Veterinary microbiology
ISSN: 1873-2542
Titre abrégé: Vet Microbiol
Pays: Netherlands
ID NLM: 7705469
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
03
03
2023
revised:
15
06
2023
accepted:
18
06
2023
medline:
4
9
2023
pubmed:
25
6
2023
entrez:
24
6
2023
Statut:
ppublish
Résumé
The MS-H vaccine strain (Vaxsafe MS®; Bioproperties Pty. Ltd., Australia) is a live attenuated temperature sensitive derivative of a virulent strain of M. synoviae, 86079/7NS, and is used to prevent diseases from M. synoviae challenges in poultry farms. The genome sequence of MS-H includes 32 single nucleotide polymorphisms (SNPs) compared to that of 86079/7NS. To investigate the nature of mutations responsible for temperature sensitivity, MS-H strain was subjected to thermal adaptation in vitro and in vivo. The only observed variation detected in the MS-H culture following sequential passages with incremental incubation temperature from 33 °C to 39.5 °C was an Ala210Val variation in Obg protein, associated with loss of temperature sensitivity phenotype. An identical variation was detected in the MS-H culture reisolated from one out of five bird 28 days after inoculation with MS-H. These findings suggest that M. synoviae is capable of thermoadaptive evolution and Obg plays a significant role in this trait.
Identifiants
pubmed: 37354700
pii: S0378-1135(23)00170-0
doi: 10.1016/j.vetmic.2023.109818
pii:
doi:
Substances chimiques
Vaccines, Attenuated
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
109818Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: This study was funded by the Australian Research Council and Bioproperties Pty. Ltd., Australia through the ARC Linkage Project grant LP180100762. The MS-H vaccine is produced by Bioproperties Pty. Ltd., Australia.